Iodine-123 ioflupane - Intravenous Injectable Form

This tender concerns the procurement of Iodine-123 ioflupane, specifically in an intravenous injectable form. Each unit is specified as containing 74 MBq per 1 ml, with a volume of 2.5 ml. Lot 1 of this procurement corresponds to 70% of the annual needs of the purchasing institutions ('Établissements'). Iodine-123 ioflupane is a radiopharmaceutical used in medical imaging, particularly for diagnosing and monitoring conditions such as Parkinson's disease and other related movement disorders. It is a tracer that binds to dopamine transporters in the brain, allowing for visualization of dopaminergic pathways through SPECT (Single-Photon Emission Computed Tomography) imaging. The tender is seeking a reliable supply of this critical diagnostic agent. The specified quantity for Lot 1 indicates a significant portion of the annual requirement, suggesting a substantial demand. The procurement process will likely involve stringent quality control measures to ensure the radiopharmaceutical meets all regulatory and clinical standards for safety and efficacy. Further details regarding the supplier qualifications, delivery schedules, and specific usage protocols are expected within the complete tender documents.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Luxembourg, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.